Encoded closes $275M Series F for Dravet syndrome drug
Encoded Therapeutics has tacked on $275 million in new capital, closing a Series F round led by GV and an undisclosed healthcare investor. The precision genetic medicine biotech said Wednesday that ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.